Effect of Different Ablative Doses of Radioactive Iodine in Patients with Differentiated Thyroid Carcinoma and Cervical Lymph Node Metastasis | ||
| SECI Oncology Journal | ||
| Volume 11, Issue 2, May 2023, Pages 131-138 | ||
| Abstract | ||
| Background: Thyroid cancer is the most prevalent endocrine malignancy accounting for 2% of all cancers in Egypt. Differentiated thyroid cancer (DTC) is the most histopathological subtype. Surgery with postoperative radioactive iodine (RAI) ablation is the standard treatment. Cervical lymph node metastasis is most popular site of metastasis. Objective: The study aims to assess the effect of different doses of RAI 131I on progression free survival (PFS) and overall survival (OAS) in patients with DTC and cervical LN metastasis. Patients and Methods: Seventy patients with DTC with cervical lymph node metastasis who had been seen at the Clinical Oncology Department, Mansoura University Hospitals between 1st of 2015 to the end of 2020 were included in this retrospective analysis. Results: Male to female ratio was 1:1.8. The mean age was 40.98 (SD ± 14.34) years ranging from 18-69 years. Papillary thyroid carcinoma (PTC) represented 62 patients (88.6%). Fifty-seven (81.4 %) of patient were presented with stage I disease. Mean OAS was 64.01 (SD ± 14.18) ranging from 15-92 months. The 2- year PFS was 88.6% with mean PFS 46 (SD ±19.7). OAS prognostic factors were stage, tumor size (T-stage), presence of ECE or patient performance status (p-value = <0.001, 0.002, 0.041, and 0.024 respectively). Conclusion: The high postoperative TG, PNI, ENE and higher number of involved LNs have negative clinical outcome. RAI ablation is essential for the right patient after confirming the risk category to improve the course of the disease, increase survival rates, and stop additional recurrences. | ||
| Keywords | ||
| RAI 131; Ablative dose; DTC; cervical lymph node; thyroid cancer | ||
|
Supplementary Files
|
||
|
Statistics Article View: 89 |
||
